Global initiative IDs keys that could unlock better personalized cancer treatments
The Tumor Neoantigen Selection Alliance (TESLA) has discovered five characteristics that strongly indicated which cancer markers were most likely to generate an immune response. The data model accurately predicted 75% of effective neoantigen targets and filtered out 98% of ineffective ones.